Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00758212|
Recruitment Status : Unknown
Verified September 2008 by Hadassah Medical Organization.
Recruitment status was: Enrolling by invitation
First Posted : September 25, 2008
Last Update Posted : October 9, 2008
|Condition or disease||Intervention/treatment||Phase|
|Influenza Acquired Immune Deficiency Syndrome HIV Infections||Biological: Mesotherapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Influenza Vaccination at a Reduced Dose of 1:10 Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||January 2009|
|Estimated Study Completion Date :||April 2009|
The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
Other Name: Vaxigrip Trivalent Influenza vaccine , diluted 1:10.
- anti influenza antibody using Hemagglutination inhibition [ Time Frame: 1 , 3 , 6 months ]
- acceptability of influenza vaccination using mesotherapy [ Time Frame: 1month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00758212
|Hadassah U. hospital|
|Principal Investigator:||shlomo maayan, md||Hadassah Medical Organization|